ABCB1 and chronic myelogenous leukemia, BCR-ABL1 positive: Resistance to imatinib, a first-line BCR-ABL1 tyrosinekinase inhibitorfor chronic myeloid leukemia, is frequently mediated by drug effluxthrough P-glycoprotein (P-gp) overexpression.